ResMed — Aug 6, 2026 release

For full year 2026, our $1.6 billion in free cash flow enabled us to invest in innovation, strengthen our market leadership, and return more than $1 billion to our shareholders.” “As we enter fiscal year 2027, we will leverage our global scale and enhance our digital capabilities to benefit our patients, providers, and customers. We will use our industry-leading portfolio to improve patient outcomes, reduce healthcare costs, and drive long-term profitable growth for our shareholders.” Financial Highlights     •   FY 2026 revenue increased by 10% to $5.7 billion; up 8% on a constant currency basis     •   FY 2026 GAAP gross margin up 170 bps to 61.1%; non-GAAP gross margin up 240 bps to 62.4%     •   FY 2026 GAAP operating margin up 70 bps to 33.4%, non-GAAP operating margin up 180 bps to 36.1%     •   FY 2026 GAAP diluted earnings per share of $10.43; non-GAAP diluted earnings per share of $11.17, an increase of 17%     •   FY 2026 operating cash flow of $1.8 billion; free cash flow of $1.6 billion     •   Guiding to more than $1.85 billion in capital to be returned to shareholders through share repurchases and dividends during FY 2027; announced quarterly dividend increase of 10% to $0.66 per quarter Other Business and Operational Highlights     •   Announced agreement to sell MatrixCare business; transaction expected to close during the first quarter of Resmed’s fiscal year 2027.     •   Completed acquisition of Noctrix Health, a medical device company selling FDA De Novo classified wearable therapeutics for Restless Leg Syndrome, or RLS.     •   Partnered with ŌURA to expand access to sleep health education and pathways to care, helping more people sleep better and improve their overall health.     •   Following other successful launches in APAC, EMEA and the Americas, launched AirSense 11 in Taiwan. Additionally, launched AirCurve 11 ST/ST-A in the U.S. and AirTouch F30i Comfort in Brazil and Chile. RMD Fourth Quarter 2026 Earnings Press Release – August 6, 2026    Page 2 of 10   Financial Results and Operating Metrics Unaudited; $ in millions, except for per share amounts